Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-20-031340)

Name of Reporting Person

I.R.S. Identification No. of Above Person (Entities Only)

Hatteras Venture Partners IV SBIC, L.P.

Check the Appropriate Box if a Member of a Group

(a) ☐ (b) ☐

Not Applicable

SEC Use Only

Citizenship or Place of Organization

Delaware

Accession Number:: 0001193125-20-031340
Form Type:: 13G Filing
Publication Date:: 2020-02-11 16:20:05

Filed By:: Hatteras Venture Partners Iv Sbic, Lp
Company:: G1 Therapeutics Inc. (NASDAQ:GTHX)
Filing Date:: 2020-02-11
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Hatteras Venture Partners IV SBIC	0	1,910,126	0	1,910,126	1,910,126	5.1%
Hatteras Venture Advisors IV SBIC	0	1,910,126	0	1,910,126	1,910,126	5.1%
Hatteras NC Fund	0	104,957	0	104,957	104,957	Less than 1%
Hatteras Venture Advisors IV	0	104,957	0	104,957	104,957	Less than 1%
Hatteras Venture Partners IV	0	104,957	0	104,957	104,957	Less than 1%
Hatteras Venture Advisors V	0	995	0	995	995	Less than 1%
Hatteras Venture Partners V	0	995	0	995	995	Less than 1%
John C. Crumpler	0	2,016,088	0	2,016,088	2,016,088	5.4%
Clay B. Thorp	300	2,016,088	300	2,016,088	2,016,388	5.4%
Christy Shaffer	0	995	0	995	995	Less than 1%
Kenneth B. Lee	0	2,015,093	0	2,015,093	2,015,093	5.4%
Douglas Reed	0	2,016,088	0	2,016,088	2,016,088	5.4%
Robert A. Ingram	0	2,016,088	0	2,016,088	2,016,088	5.4%

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Amendment No. 2)*

Under the Securities Exchange Act of 1934

G1 Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

3621LQ109

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing of this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 3621LQ109

Page 2 of 20

CUSIP No. 3621LQ109

Page 3 of 20

CUSIP No. 3621LQ109

Page 4 of 20

CUSIP No. 3621LQ109

Page 5 of 20

CUSIP No. 3621LQ109

Page 6 of 20

CUSIP No. 3621LQ109

Page 7 of 20

CUSIP No. 3621LQ109

Page 8 of 20

CUSIP No. 3621LQ109

Page 9 of 20

CUSIP No. 3621LQ109

Page 10 of 20

CUSIP No. 3621LQ109

Page 11 of 20

CUSIP No. 3621LQ109

Page 12 of 20

CUSIP No. 3621LQ109

Page 13 of 20

CUSIP No. 3621LQ109

Page 14 of 20

CUSIP No. 3621LQ109

Page 15 of 20

Item 1(a)

Name of Issuer

G1 Therapeutics, Inc. (the Issuer)

Item 1(b)

Address of Issuers Principal Executive Offices

700 Park Office Drive, Suite 200, Research Triangle Park, North Carolina 27709.

Item 2(a)

Name of Person Filing

This Amendment No. 2 to Schedule 13G is being filed by:

Hatteras Venture Partners IV SBIC, L.P. (HVP SBIC)

Hatteras Venture Advisors IV SBIC, LLC (HVA SBIC)

Hatteras NC Fund, L.P. (Hatteras Fund)

Hatteras Venture Advisors IV, LLC (HVA IV)

Hatteras Venture Partners IV, L.P. (HVP IV)

Hatteras Venture Advisors V, LLC (HVA V)

Hatteras Venture Partners V, L.P. (HVP V)

John C. Crumpler

Clay B. Thorp

Christy Shaffer

Kenneth B. Lee

Douglas Reed

Robert A. Ingram

(collectively, the Reporting Persons).

Item 2(b)

Address of Principal Business Office, or if none, Residence

280 S. Mangum Street, Suite 350, Durham, North Carolina 27701.

Item 2(c)

Citizenship

The Reporting Persons are citizens of:

HVP SBIC Delaware

HVA SBIC Delaware

Hatteras Fund Delaware

HVA IV North Carolina

HVP IV Delaware

HVA V North Carolina

HVP V Delaware

John C. Crumpler USA

Clay B. Thorp USA

Christy Shaffer USA

Kenneth B. Lee USA

Douglas Reed USA

Robert A. Ingram USA

CUSIP No. 3621LQ109

Page 16 of 20

Item 2(d)

Title of Class of Securities

Common Stock, par value $0.0001 per share (Common Stock)

Item 2(e)

CUSIP Number

3621LQ109

Item 3.

Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c)

Not Applicable

Item 4.

Ownership

(a) The Reporting Persons are the beneficial owners of an aggregate of 2,016,088 shares of Common Stock, which represents 5.4% of the Issuers outstanding Common Stock based upon 37,581,512 shares outstanding on October 31, 2019 as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2019 as filed with the Securities and Exchange Commission on November 5, 2019. The Reporting Persons beneficial ownership consists of 1,910,126 shares of Common Stock held directly by HVP SBIC, 104,967 shares of Common Stock held directly by Hatteras Fund and 995 shares of Common Stock held directly by HVA V.

HVA SBIC is the general partner of HVP SBIC. HVA IV is the general partner of HVP IV and Hatteras Fund. HVA V is the general partner of HVP V. The shares are held directly by HVP SBIC, Hatteras Fund and HVA V. The shares held by HVP SBIC and Hatteras Fund are indirectly held by the individual managing members of the general partners, HVA SBIC and HVA IV, respectively, (collectively, the GP Managing Members). The GP Managing Members are John C. Crumpler, Clay B. Thorp, Kenneth B. Lee, Douglas Reed and Robert A. Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP SBIC and Hatteras Fund. The shares held by HVA V are indirectly held by the individual management members of the general partner, HVP V (the Managing Members). The Management Members are John C. Crumpler, Clay B. Thorp, Christy Shaffer, Douglas Reed and Robert A. Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V.

(b) Percent of class:

HVP SBIC 5.1%

HVA SBIC 5.1%

Hatteras Fund Less than 1%

HVA IV Less than 1%

HVP IV Less than 1%

HVA V Less than 1%

HVP V Less than 1%

John C. Crumpler 5.4%

Clay B. Thorp 5.4%

Christy Shaffer Less than 1%

Kenneth B. Lee 5.4%

Douglas Reed 5.4%

Robert A. Ingram 5.4%

CUSIP No. 3621LQ109

Page 17 of 20

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote:

HVP SBIC 1,910,126

HVA SBIC 1,910,126

Hatteras Fund 104,967

HVA IV 104,967

HVP IV 104,967

HVA V 995

HVP V 995

John C. Crumpler 2,016,088

Clay B. Thorp 2,016,388

Christy Shaffer 995

Kenneth B. Lee 2,015,093

Douglas Reed 2,016,088

Robert A. Ingram 2,016,088

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of:

HVP SBIC 1,910,126

HVA SBIC 1,910,126

Hatteras Fund 104,967

HVA IV 104,967

HVP IV 104,967

HVA V 995

HVP V 995

John C. Crumpler 2,016,088

Clay B. Thorp 2,016,388

Christy Shaffer 995

Kenneth B. Lee 2,015,093

Douglas Reed 2,016,088

Robert A. Ingram 2,016,088

Item 5.

Ownership of Five Percent or Less of a Class

Not Applicable

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

CUSIP No. 3621LQ109

Page 18 of 20

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8.

Identification and Classification of Members of the Group

Not Applicable

Item 9.

Notice of Dissolution of Group

Not Applicable

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Exhibit Index

Exhibit A Agreement Regarding the Joint Filing of Schedule 13G is incorporated by reference to Exhibit A to the Schedule 13G filed by the Reporting Persons on February 13, 2018.

Exhibit B Power of Attorney is incorporated by reference to Exhibit B to the Schedule 13G filed by the Reporting Persons on February 13, 2018.

CUSIP No. 3621LQ109

Page 19 of 20

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 11, 2020


HATTERAS VENTURE PARTNERS IV SBIC, L.P.

By:		Hatteras Venture Advisors IV SBIC, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE ADVISORS IV SBIC, LLC

By:		/s/ Clay B. Thorp
		Manager

HATTERAS NC FUND, L.P.

By:		Hatteras Venture Advisors IV, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE ADVISORS IV, LLC

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE PARTNERS IV, L.P.

By:		Hatteras Venture Advisors IV, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

HATTERAS VENTURE ADVISORS V, LLC

By:		/s/ Clay B. Thorp
		Manager

CUSIP No. 3621LQ109

Page 20 of 20



HATTERAS VENTURE PARTNERS V, L.P.

By:		Hatteras Venture Advisors V, LLC, its general partner

By:		/s/ Clay B. Thorp
		Manager

*
John C. Crumpler

*
Clay B. Thorp

*
Christy Shaffer

*
Kenneth B. Lee

*
Douglas Reed

*
Robert A. Ingram

By:		/s/ Clay B. Thorp
		Clay B. Thorp, as Attorney-in-Fact

*	This Amendment No. 2 to Schedule 13G was executed by Clay B. Thorp on behalf of the filers listed above pursuant to a Power of Attorney, a copy of which was previously filed with the Reporting Persons Schedule 13G filed with the SEC on February 13, 2018.